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Chronic abdominal pain is the primary symptom of chronic pancreatitis, but unfortunately it
is difficult to treat. Vagal nerve stimulation studies have provided evidence of anti-nocicep-
tive effect in several chronic pain conditions. We investigated the pain-relieving effects of
transcutaneous vagal nerve stimulation in comparison to sham treatment in chronic pancre-
atitis patients.
Methods
We conducted a randomised double-blinded, sham-controlled, crossover trial in patients
with chronic pancreatitis. Patients were randomly assigned to receive a two-week period of
cervical transcutaneous vagal nerve stimulation using the gammaCore device followed by a
two-week sham stimulation, or vice versa. We measured clinical and experimental end-
points before and after each treatment. The primary clinical endpoint was pain relief, docu-
mented in a pain diary using a visual analogue scale. Secondary clinical endpoints included
Patients’ Global Impression of Change score, quality of life and Brief Pain Inventory ques-
tionnaire. Secondary experimental endpoints included cardiac vagal tone and heart rate.
Results
No differences in pain scores were seen in response to two weeks transcutaneous vagal
nerve stimulation as compared to sham treatment (difference in average pain score (visual
analogue scale): 0.17, 95%CI (-0.86;1.20), P = 0.7). Similarly, no differences were seen for
secondary clinical endpoints, except from an increase in the appetite loss score (13.9, 95%
CI (0.5:27.3), P = 0.04). However, improvements in maximum pain scores were seen for
transcutaneous vagal nerve stimulation and sham treatments as compared to their
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respective baselines: vagal nerve stimulation (-1.3±1.7, 95%CI (-2.21:-0.42), P = 0.007),
sham (-1.3±1.9, 95%CI (-2.28:-0.25), P = 0.018). Finally, heart rate was decreased after two
weeks transcutaneous vagal nerve stimulation in comparison to sham treatment (-3.7
beats/min, 95%CI (-6.7:-0.6), P = 0.02).
Conclusion
In this sham-controlled crossover study, we found no evidence that two weeks transcutane-
ous vagal nerve stimulation induces pain relief in patients with chronic pancreatitis.
Trial registration number
The study is registered at NCT03357029; www.clinicaltrials.gov.
Introduction
Chronic abdominal pain is the primary symptom of chronic pancreatitis (CP) and seen in the
majority of patients during the course of disease [1]. Recent studies have provided evidence
that CP patients have abnormal pain processing in the central nervous system [2]. Hence, sus-
tained pancreatic nociceptive afferent inputs can over time result in sensitization of peripheral
and central nociceptive pathways characterized by neuronal hyper-responsiveness. This can
potentially lead to a chronic state of pain independent of peripheral nociceptive input, and
patients typically respond inadequate to therapies directed against pathophysiological changes
of the pancreas [1].
Vagal nerve stimulation (VNS) is a potential new non-pharmacological treatment targeting
the autonomic and central nociceptive pathways. Previous studies have demonstrated that
VNS provided analgesic effects in several painful conditions including fibromyalgia, pelvic
pain and headache [3–5]. That has increased awareness of the potential of non-invasive vagal
nerve stimulation (nVNS), and several medical devices are marketed. A study from our group,
in healthy volunteers, showed that electrical and physiological modulation of parasympathetic
tone resulted in pain attenuation [6], indicating that the parasympathetic nervous system is
broadly anti-nociceptive [7]. nVNS has also shown its effect in clinical settings. Hence, two
sham-controlled randomised controlled trials and six single-arm studies, demonstrated both
rapid pain relief and a long term prophylactic effect of nVNS when used adjunctively with
standard treatment in episodic and chronic migraine headaches [8]. The anatomical projec-
tions of the vagal nerve and its connections with many different brain areas involved in pain
perception enables a potential analgesic effect [5]. The vagal nerve has widespread projections
throughout the abdominal and pelvic viscera, thus a likely target of VNS could be abdominal
pain in CP [9].
Based on the limited effectiveness of conventional treatments of CP pain, we hypothesized
that two weeks nVNS could be effective as an adjuvant treatment to alleviate pain and improve
quality of life in CP patients. The aims of this study were: 1) to primary evaluate the effects of
two weeks nVNS on pain symptoms and quality of life by comparing nVNS treatment to sham
treatment and 2) to investigate whether nVNS had an effect on modulating the autonomic ner-
vous system. Finally, explorative analyses were provided comparing nVNS and sham treat-
ment to their baselines.
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Materials and methods
Study overview
This study was an investigator-initiated, randomised, double-blinded, sham-controlled, cross-
over clinical trial assessing the effect of cervical nVNS for pain treatment in patients with CP
(Fig 1). The study was conducted at Aalborg University Hospital, Denmark from January 2018
to April 2019. As active nVNS treatment, an FDA approved medical device (gammaCore-S,
ElectroCore LLC, Basking Ridge, New Jersey, USA) was used, and the sham devices were iden-
tical in appearance (ElectroCore LLC, Basking Ridge, New Jersey, USA). The North Denmark
Region Committee on Health Research Ethics (N-20170023) and the Danish Medical Agency
(2017023686) approved the study. Furthermore, the study was registered at Clinicaltrials.gov
(NCT03357029). This study was conducted in accordance with the Declaration of Helsinki,
and consistent with Good Clinical Practice. For more information on the study design, please
refer to the study protocol which has been published in BMJ Open [10] (S1 Appendix CON-
SORT checklist and protocol).
Inclusion of CP patients
Patients from the age of 18 years with a diagnosis of CP, based on the Mayo Clinic diagnostic
criteria [11], were included regardless of the aetiology of CP. The included patients suffered
from chronic abdominal pain more than 3 days per week lasting longer than 3 months, and
they should consider their pain as insufficiently treated with usual analgesic treatments. All
patients were required to read and understand Danish and to be able to comply with the
scheduled visits and procedures. All participants signed and dated the informed consent and
the Power of attorney document from the Danish Medical Agency [10]. Exclusion criteria
were ongoing alcohol dependence, illegal drug dependencies, participating in other studies
Fig 1. CONSORT diagram. Study enrolment and randomisation.
https://doi.org/10.1371/journal.pone.0247653.g001
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where an investigational drug was used. Patients with any clinically significant abnormalities
that in the opinion of the investigator could increase the risk associated with trial participation
were excluded. Moreover, patients with cardiovascular diseases, low blood pressure (<100/
60), elevated intracranial pressure, female patients who were pregnant or lactating, contraindi-
cations for magnetic resonance imaging, previous surgery on the vagal nerve, and patients
with known neuropathy were excluded. Patients were also excluded during the study, if they
did not maintain the eligibility criteria during the study period [10]. All patients were asked to
maintain their usual pain medication and dosage during the entire study, and they were only
allowed to take extra pain medication in case of severe pain attacks. Any changes needed in
pain medication during the study period was noted by the patient in the pain diary. Patients
were allowed to continue the following analgesics during the study period: paracetamol, non-
steroidal anti-inflammatory drug (NSAID), opioids, tricyclic antidepressant (TCA), serotonin-
norepinephrine reuptake inhibitor (SNRI) and gabapentoids.
Randomisation and blinding
Included patients were randomly assigned in two sequences (order of treatments: nVNS/sham
or sham/nVNS) using block randomisation, allowing seven patients at the time to be rando-
mised. The randomisation list was generated by an automatic web-based randomisation pro-
gram. Patients and those administrating medical devices and assessing the outcomes were
blinded to the group assignment.
Interventions
The active treatment (nVNS) was performed using the medical device gammaCore-S, which is
commercially available and FDA-approved for the treatment of primary headache [8]. The
sham treatment was performed using a sham device. The two devices were identical in appear-
ance, weight, visual and audible feedback, but the sham device did not deliver electrical stimuli
(only a vibration). Patients were instructed to self-administer the treatment bilaterally on the
neck three times per day for two weeks at home. Two weeks stimulation was chosen, since pre-
vious prospective, double-blind, sham-controlled, randomized studies with transcutaneous
VNS have demonstrated that stimulations with gammaCore induced a pain reliving effect at
30, 60 and 120 minutes in migraine patients [12]. Therefore, we expected that two weeks
would be sufficient to induce a long-term pain-relieving effect. The treatment was delivered
via two stainless steel contact surfaces that were covered with conductive gel before each treat-
ment (Fig 2). Next, the device was positioned in parallel with the carotid artery on the neck.
One stimulation had a duration of two minutes [13]. On the first day before treatment, patients
were trained on correct positioning and instructed to adjust the stimulation intensity using
+/–buttons on the device to achieve a comfortable and sufficient sensation. The sufficient sen-
sation was gained, when the patient step-by-step increased the intensity of the stimulation,
which induced mild pain and unpleasantness. Then, the intensity was decreased one step
immediately. The intensity of the stimulation varied from 1 to 40 units, and patients registered
the intensity of the stimulation after each treatment in the pain diary. The treatment periods
were separated by a two-week wash-out period. The patients continued their usual analgesic
medication during the wash-out period. The two week wash-out period has been used in previ-
ous studies of neuromodulation and shown to be sufficient to reset the effects of neuromodula-
tion [10].
Compliance was assessed by reading the remaining stimulations on the device display after
each treatment period. Throughout both treatment periods, all patients were asked to register
any adverse events using an adverse events questionnaire.
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Clinical assessment of pain and quality of life
The primary clinical endpoint was to evaluate the effects of two weeks nVNS on pain symp-
toms and quality of life compared to two weeks of sham treatment. The daily experience of
pain (the maximum pain intensity and the average pain intensity) was measured using a pain
diary based on a visual analogue scale (VAS), with 0: no pain, and 10: worst pain imaginable
[14]. All patients were instructed to fulfil the pain diary every day during the entire 8-week
study period, starting with baseline measurements for seven consecutive days before the first
treatment. One baseline measurement and the effect of two weeks treatment on pain symp-
toms were measured as an average of the pain scores for the last four days of the baseline and
treatment periods, respectively.
The secondary clinical endpoints included three questionnaires; 1) the European Organiza-
tion for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
[15], 2) Brief Pain Inventory (BPI) short form questionnaire [16], and 3) Patient’s Global
Impression of Change (PGIC) [17]. EORTC QLQ-C30 and BPI questionnaires were fulfilled
before and after each treatment period, while the PGIC score was assessed at the end of each
treatment period.
Assessment of parasympathetic modulation effects
To investigate whether nVNS was able to modulate the cardiac vagal tone (CVT) in CP
patients, the parasympathetic modulation was assessed using the electrocardiography (ECG)
recorder device eMotion Faros 180 (Mega Electronics Ltd, Kuopio, Finland) [18]. First, the
patients were instructed to rest for five minutes. Next, ECG electrodes (Ambu Blue Sensor P,
Denmark) were placed in the left and right subclavicular areas and cardiac apex and then
Fig 2. Study design & treatment procedure: Patients were instructed to self-administer the treatment bilaterally
on the neck three times per day for two weeks at home. The treatment was delivered via two stainless steel contact
surfaces that were covered with conductive gel before each treatment.
https://doi.org/10.1371/journal.pone.0247653.g002
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attached to a non-invasive cardiac monitor. A biosignal acquisition system (ExtremeBio-
metrics, London, UK) was used to assess cardiac derived parameters from five minutes record-
ings. Recordings were conducted before and after two weeks of nVNS/sham treatment.
Similarly, recordings were also conducted after two weeks of nVNS/sham treatment.
Based on the ECG recording, CVT was assessed as a measure of the influence of the para-
sympathetic nervous system on the heart through the vagal nerve, which originates in the
brain stem. CVT was calculated beat-to-beat based on detecting positive phase shifts in the
R-R interval and used as a putative measurement of heart rate variability [18]. Thus, low CVT
values reflect low heart rate variability, whereas high values reflect high heart rate variability.
CVT was measured on a linear vagal scale (LVS) [18]. Before analysis, data were cleaned for
noise, meaning that the first 10 samples of data were removed. Also, heart rate data points
deviating from beat-to-beat with>15 beats pr. minute were removed, due to non-physiologi-
cal causative factors. Since the consecutive R-R intervals affect the CVT measure, the previous
and following 7 samples were also removed. Finally, heart rate was measured before and after
both treatments.
Statistical analyses
The study was powered to detect a minimal difference in average daily pain scores of 30%
between nVNS and sham treatment. Based on a standard deviation (SD) of 40%, we deter-
mined that a study with 16 patients in a crossover design was needed to provide a power of
80% with the use of a 2-sided significance level of 0.05 [10].
All data are presented as mean and SD unless otherwise stated. The continues variables
were checked for normality using Shapiro-Wilk test. Before the primary analysis was per-
formed, we defined the intensity of pain as an average of the scores for pain in the patient’s
diary for the last 4 days in each treatment period [19]. For analysis of the primary endpoint,
the difference in pain intensities between the two treatment sequences (nVNS/sham and
sham/nVNS) were calculated for each patient and compared using a t-test for independent
samples. The assumption that the wash-out phase was long enough to rule out a carry-over
effect was checked in a pretest by calculating the sum of pain intensity scores for each subject
and comparing these across the two sequence groups by means of a t-test for independent
samples [20]. Changes in secondary continues endpoints (BPI, EORTC QLQ-C30, CVT data)
were analyzed using a similar approach. Data on compliance was transformed to a relative
scale (%) and analysed using a paired sample t-test. Categorical data (PGIC and adverse
events) were analyzed using a McNemar test. Finally, one-sample t-tests were used to further
analyse the difference for 1) nVNS vs. baseline, and 2) sham vs. baseline (within group analy-
sis). All the statistical analyses were performed using statistical software package STATA
V.16.1 (StataCorp LP, College Station). P-values <0.05 were considered statistically
significant.
Results
Patient enrolment and clinical characteristics
Fifty-three patients were screened and 28 underwent randomisation (Fig 1). Twenty-two
patients completed the baseline assessment. 17 patients completed the first treatment period
and 16 patients completed both treatment periods. Demographic and clinical characteristics of
the enrolled patients (n = 22) and for patients completing the study (n = 16) are summarized
in Table 1. Characteristics for patients in each sequence (nVNS/sham, n = 4 and sham/nVNS,
n = 12) are provided in Supporting information (S1 Table: Demographics by sequences). Five
out of six dropouts were assigned to the nVNS/sham sequence. No patients dropped out due
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to adverse effects or non-tolerance of the interventions. In the nVNS treatment, 98%±3% of all
stimulations were applied compared with 94%±11% in the sham treatment (P = 0.24). Further-
more, the average intensity of the stimulations was 31.8±6.9 units during nVNS treatment and
36.0±7.9 units for sham treatment (P = 0.02).
Primary and secondary clinical outcomes
nVNS vs. sham. Primary and secondary clinical endpoints (after two weeks intervention)
are summarized in Table 2. No significant differences were observed for the maximal or
Table 1. Demographic and clinical characteristics of chronic pancreatitis patients.
Variables Chronic pancreatitis patients
Included in study (n = 22) Completed study (n = 16)
Age (years) 55.2±8.9 56.6±9.4
Male, n (%) 18 (81.8) 14 (88)
Body mass index (kg/m2) 22.5±4.6 21.9±3.6
Aetiology of chronic pancreatitis, n (%)
Alcohol 13 (35) 11 (42)
Nicotine 15 (41) 10 (38)
Nutritional 0 (0) 0 (0)
Hereditary factors 3 (8) 2 (8)
Efferent duct factors 5 (13) 3 (12)
Immunological factors 0 (0) 0 (0)
Miscellaneous and rare metabolic factors 1 (3) 0 (0)
Duration of chronic pancreatitis (years) 8.1±7.6 9.7±8.4
Diabetes, n (%) 11 (50) 9 (56)
Analgesics, n (%)
Paracetamol 14 (64) 11 (36)
NSAID 2 (9) 1 (3)
Opioids 19 (86) 13 (42)
Adjuvant analgesics, n (%) 1 (5) 1 (3)
TCA 0 (0) 0 (0)
SNRI Gabapentoids 7 (32) 5 (16)
Current alcohol use, n (%)
0 units 12 (55) 8 (50)
1–5 units 5 (23) 3 (19)
5–10 units 5 (23) 5 (31)
10–15 units 0 (0) 0 (0)
>20 units 0 (0) 0 (0)
Current smoking pattern, n (%)
non-smoker 5 (23) 4 (25)
1–5 cigarettes per day 3 (14) 2 (13)
5–10 cigarettes per day 2 (9) 2 (13)
10–15 cigarettes per day 3 (14) 2 (13)
15–20 cigarettes per day 6 (27) 3 (19)
>20 cigarettes per day 3 (14) 3 (19)
Note: Values are means ± SD. Percentages may not total 100 due to rounding.
Abbreviations: n = number of patients. NSAID = Nonsteroidal anti-inflammatory drug. TCA = Tricyclic
antidepressant. SNRI = Serotonin-norepinephrine reuptake inhibitor.
https://doi.org/10.1371/journal.pone.0247653.t001
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average pain score between two weeks nVNS treatment vs. sham treatment (difference in aver-
age pain score (visual analogue scale): 0.17, 95%CI (-0.86;1.20), P = 0.7) (Fig 3 and Supporting
information (S1 Fig: Individual plots of the maximal and average pain scores)). Likewise, no
differences were seen for secondary clinical endpoints, except from a significant increase in
Table 2. Primary and secondary clinical endpoints after two weeks of nVNS and sham treatment.
Primary clinical endpoints Pain diary
Variables Sequence Treatment period Mean
±SD
Within-individual differences for nVNS vs. sham Treatment effect for nVNS vs. sham (95% CI) P (effect) P (carry-over)
1 2
Average pain score (VAS) nVNS/sham 2.9±1.8 2.2±2.1 0.34±0.61 0.17 (-0.86:1.20) 0.72 0.49
sham/nVNS 3.6±2.5 3.3±2.4 -0.17±0.88
Maximal pain score (VAS) nVNS/sham 4.1±2.3 3.4±2.7 0.34±0.77 0.20 (-1.14:1.54) 0.76 0.56
sham/nVNS 4.6±2.6 4.4±2.5 -0.15±1.15
Secondary clinical endpoints Brief Pain Inventory questionnaire
BPI Pain nVNS/sham 3.1±2.1 2.8±2.5 0.1±0.4 0.19 (-1.11:1.48) 0.76 0.40
sham/nVNS 3.9±2.2 4.0±2.4 0.1±1.2
BPI Interference nVNS/sham 2.0±1.2 2.1±1.1 -0.1±0.2 -0.006 (-1.17:1.15) 0.99 0.13
sham/nVNS 3.8±2.1 3.9±2.6 0.0±1.0
Quality of life
Global health status nVNS/sham 64.6±19.7 66.7±22.6 -1.0±4.0 -1.04 (-13.1:11.0) 0.86 0.13
sham/nVNS 50.7±15.7 50.7±20.2 0.0±10.8
Physical functioning nVNS/sham 86.7±34.9 78.3±14.8 4.2±17.3 4.44 (-7.3:16.2) 0.43 0.04
sham/nVNS 59.4±18.1 60.0±17.3 0.3±5.8
Role functioning nVNS/sham 83.3±16.7 79.2±16.0 0.0±8.3 3.5 (-7.2:14.1) 0.49 0.08
sham/nVNS 50.0±24.6 56.9±28.8 3.5±7.5
Emotional functioning nVNS/sham 81.3±14.2 81.3±14.2 0.0±3.4 -1.7 (-13.5:10.0) 0.76 0.09
sham/nVNS 65.3±20.4 61.8±21.2 -1.7±10.6
Cognitive functioning nVNS/sham 83.3±19.2 87.5±16.0 -2.1±4.2 -2.1 (-12.7:8.5) 0.68 0.02
sham/nVNS 55.6±25.9 55.6±17.9 0.0±9.4
Social functioning nVNS/sham 83.3±19.2 87.5±16.0 -2.1±4.2 -4.2 (-16.2:7.9) 0.47 0.15
sham/nVNS 66.7±23.6 62.5±30.3 -2.1±10.7
Fatigue nVNS/sham 29.6±17.0 22.2±18.1 7.4±3.2 6.5 (-7.5:20.5) 0.34 0.16
sham/nVNS 45.4±20.9 43.5±30.9 -0.9±10.8
Nausea and vomiting nVNS/sham 0.0±0.0 0.0±0.0 0.0±0.0 1.4 (-8.0:10.8) 0.76 0.19
sham/nVNS 5.6±8.2 8.3±16.7 1.4±8.6
Pain nVNS/sham 45.8±25.0 33.3±13.6 6.2±8.0 4.2 (-13.1:21.4) 0.61 0.12
sham/nVNS 59.7±21.9 55.6±25.9 -2.1±15.1
Dyspnoea nVNS/sham 0.0±0.0 16.7±19.2 -5.6±9.6 -6.9 (-24.7:10.8) 0.41 0.28
sham/nVNS 22.2±25.9 19.4±26.4 -1.4±13.2
Insomnia nVNS/sham 11.1±19.2 16.7±33.3 5.6±9.6 6.9 (-25.7:39.5) 0.65 0.06
sham/nVNS 38.9±37.2 41.7±37.9 1.4±25.1
Appetite loss nVNS/sham 22.2±19.2 8.3±16.7 11.1±9.6 13.9 (0.5:27.3) 0.04 0.37
sham/nVNS 27.8±34.3 33.3±37.6 2.8±9.6
Constipation nVNS/sham 0.0±0.0 0.0±0.0 0.0±0.0 0.0 (-15.6:15.6) 1.00 0.29
sham/nVNS 13.9±30.0 13.9±26.4 0.0±14.2
Diarrhoea nVNS/sham 16.7±19.2 8.3±16.7 4.2±8.3 -2.8 (-15.9:10.4) 0.66 0.22
sham/nVNS 41.7±32.2 27.8±37.2 -6.9±11.1
Financial difficulties nVNS/sham 16.7±19.2 25.0±16.7 -4.2±8.3 0.0 (-12.3:12.3) 1.00 0.29
sham/nVNS 30.6±22.3 38.9±27.8 4.2±10.4
Secondary experimental endpoints Cardiac-derived parameters
Cardiac vagal tone (LVS) nVNS/sham 6.1±3.8 5.3±4.5 0.4±0.7 0.5 (-0.3:1.2) 0.18 0.48
sham/nVNS 4.6±1.9 4.7±1.9 0.1±0.5
Heart rate (beats/min) nVNS/sham 65.5±20.1 72.3±20.8 -3.4±2.8 -3.66 (-6.7:-0.6) 0.02 0.39
sham/nVNS 63.5±8.5 62.9±5.3 -0.3±2.4
Note: Comparisons between nVNS and sham treatments for the two treatment periods shown by treatment sequence (nVNS/sham, n = 4 and sham/nVNS, n = 12). The
difference in pain intensities between the two treatment sequences were calculated for each patient and compared using a t-test for independent samples. One patient
had missing data for role functioning, fatigue, dyspnoea, insomnia and appetite loss and one patient had missing data for cardiac vagal tone.
Abbreviations: VAS = visual analogue scale. SD = standard deviation. CI = confidence interval. nVNS = non-invasive vagal nerve stimulation. LVS = linear vagal scale.
N = number of patients.
https://doi.org/10.1371/journal.pone.0247653.t002
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the appetite loss score with higher scores observed after nVNS (13.9, 95%CI (0.5:27.3),
P = 0.04). PGIC showed no significant changes for nVNS treatment compared with sham
treatment (Table 3, P = 0.63). The primary and secondary clinical endpoints with correction
for the baseline assessments are given in Supporting information (S2 Table: The primary and
secondary clinical endpoints corrected for baseline assessments), where no changes in pain
scores were observed; however, a treatment effect of nVNS was shown with improvements in
physical functioning (14.6, 95%CI (1.3:28.0), P = 0.03) and dyspnoea (-19.4, 95%CI (-37.3:1.6),
P = 0.04).
nVNS and sham vs. baseline (within group analysis). A significant reduction was found
in the average pain scores (-0.7±1.2, 95%CI (-1.31:-0.003), P = 0.049) and the maximal pain
score (-1.3±1.7, 95%CI (-2.21:-0.42), P = 0.007) comparing nVNS treatment with baseline.
Also, significant reductions were detected in the maximal pain scores (-1.3±1.9, 95%CI (-2.28:-
0.25), P = 0.018) and trend towards a reduction in the average pain scores (-0.6±1.2, 95%CI
(-1.19:0.03), P = 0.06) for sham treatment as compared with baseline.
Secondary experimental outcomes
Cardiac-derived parameters are reported in Table 2. Compared to sham, nVNS treatment
induced a decrease in heart rate (-3.7 BPM, 95% CI (-6.7:-0.6), P = 0.02), while no change in
the CVT was observed (P = 0.18). Cardiac-derived parameters with correction for the baseline
assessments showed no significant differences between the nVNS and sham treatments (Sup-
porting information S2 Table: The primary and secondary clinical endpoints corrected for
baseline assessments).
Adverse events
Five serious adverse events (SAEs) occurred during the study. One patient had a SAE with hos-
pitalization due to acute pancreatitis in the nVNS period. Another patient had a SAE with
death during the sham treatment, but this was not related to the intervention. Two patients
had a SAE with hospitalization during the wash-out period (due to worsening of pain). During
the follow-up period, a patient was admitted due to a skin rash. All SAEs were considered to be
unrelated to the nVNS or sham treatment. There was no significant difference between the
nVNS and sham treatment on any of the adverse events. Detailed information on adverse
events are provided in Table 4.
Fig 3. Average pain score during the two study periods for the two sequences (nVNS/sham in black and sham/
nVNS in grey). VAS = visual analogue scale.
https://doi.org/10.1371/journal.pone.0247653.g003
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Table 3. Patient’s Global Impression of Change (PGIC).
PGIC, n nVNS P(exact)
None Yes 0.63
Sham None 8 1 9
Yes 3 4 7
11 5 16
Note: Distribution of improvement in PGIC induced by the nVNS and sham treatments (None: No change or worse;
Yes: Improved). Abbreviations: n = number of patients.
https://doi.org/10.1371/journal.pone.0247653.t003
Table 4. Adverse events.
Nausea, n nVNS P(exact)
None Yes 0.50
Sham None 1 0 1
Yes 2 13 15
3 13 16
Constipation, n nVNS P(exact)
None Yes 1.00
Sham None 1 0 1
Yes 0 15 15
1 15 16
Vomit, n nVNS P(exact)
None Yes 0.50
Sham None 0 0 0
Yes 2 14 16
2 14 16
Dizziness, n nVNS P(exact)
None Yes 0.63
Sham None 1 1 2
Yes 3 11 14
4 12 16
Headache, n nVNS P(exact)
None Yes 1.00
Sham None 0 2 2
Yes 2 12 14
2 14 16
Fatigue, n nVNS P(exact)
None Yes 1.00
Sham None 3 1 4
Yes 2 10 12
5 11 16
Abdominal pain, n nVNS P(exact)
None Yes 0.38
Sham None 1 1 2
Yes 4 10 14
5 11 16
(Continued)
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Discussion
To the best of our knowledge, this is the first clinical trial in CP patients evaluating the effects
of nVNS on chronic abdominal pain. Overall, we found no evidence of significant difference
in pain relief between the two treatments. A significant increase was demonstrated for appetite
loss. However, both the nVNS and sham treatments induced significant improvements in pain
scores when compared to their baselines. An enhanced parasympathetic tone was likely
induced after two weeks nVNS, as reflected as a decrease in heart rate.
Effect of nVNS in patients with chronic pain
Previous clinical and pre-clinical studies of VNS provided strong evidence of analgesic effects
in various clinical conditions including patients with fibromyalgia, pelvic pain and headaches
[3]. In contrast to our hypothesis, we found no evidence that CP patients had a significant pain
reduction comparing the nVNS and sham treatments. Interestingly, we found a reduction in
pain when comparing nVNS treatment with baseline, and the same was found for the sham
treatment. Previous clinical studies of pain treatment in CP patients have also shown an exten-
sive placebo response [21] not only in pharmacological studies, but also in studies with surgical
interventions, showing an improvement in subjective outcomes, including pain, disability and
quality of life [22,23]. Similar pattern was observed in the current study, showing a potential
sham effect in CP patients. A large pain reduction in the group receiving sham may mask the
Table 4. (Continued)
Nausea, n nVNS P(exact)
Diarrhoea, n nVNS P(exact)
None Yes 1.00
Sham None 1 1 2
Yes 2 12 14
3 13 16
Dry mouth, n nVNS P(exact)
None Yes 1.00
Sham None 2 0 2
Yes 1 13 14
3 13 16
Itching, n nVNS P(exact)
None Yes 1.00
Sham None 0 1 1
Yes 0 15 15
0 16 16
Other, n nVNS P(exact)
None Yes 0.25
Sham None 0 0 0
Yes 3 13 16
3 13 16
Note: Distribution of specific adverse events after nVNS and sham treatment (None: No adverse events; Yes: Adverse
events noted).
Abbreviations: n = number of patients.
https://doi.org/10.1371/journal.pone.0247653.t004
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genuine efficacy of nVNS, and this may explain the non-significant results when comparing
nVNS and sham treatment.
The lack of an anti-nociceptive effect following nVNS treatment, compared with sham
treatment, could be explained by only partial enhancement of the parasympathetic nervous
system to evoke anti-nociceptive effects as we only found an effect on the heart rate but not in
CVT. The lack of pain improvement may also reflect that a longer-lasting treatment is needed,
but the study could also be under-powered to detect a potential effect. Although, our findings
are inconsistent with other VNS studies where sham control was not performed, it is impor-
tant to emphasize that the influences of confounding covariates were reduced in our study as
the patients serve as their own controls. As far as we are aware, the majority of the VNS studies
were open labelled and non-crossover studies [24–27]. A study by Lange et al., provided evi-
dence that VNS may be a useful adjunct treatment for patients with fibromyalgia [24], and
Oshinsky et al. demonstrated that pain reduction was correlated with a reduction in the extra-
cellular glutamate concentration in the brain [28]. Compared to these non-crossover studies,
our current study found similar results, i.e. pain reduction comparing nVNS treatment with
baseline. Our negative findings could therefore likely be explained by the strong study-design
(double-blinded sham-controlled crossover study).
Recently, a functional MRI study showed that cervical vagal afferents can be accessed non-
invasively via transcutaneous electrical stimulation of the neck, which overlies the course of
the vagus nerve [29]. Also, the brain activation elicited by nVNS was analogous to that elicited
by invasive VNS, providing validation of cervical nVNS effects [27].
Modulation of the parasympathetic tone with nVNS in CP patients
A previous study by Brock et al., demonstrated that nVNS induced an increase in CVT and
reduced serum TNF-α in healthy volunteers, suggesting that nVNS exerts an autonomic and
anti-inflammatory effect [30]. Thus, we expected that CVT would significantly increase in CP
patients after two-week nVNS treatment as compared with sham treatment. However, we only
found a decrease in heart rate after two weeks nVNS treatment as compared with sham, but no
change in CVT. This indicates that nVNS might only be partially modulating the parasympa-
thetic tone in CP patients. This could be explained by low sample size, as the study was pow-
ered for the primary endpoint (pain scores) and not for CVT. A study by Juel et al. in CP
patients, showed that nVNS and deep slow breathing increased CVT compared to sham stimu-
lation [6]. In this study, also no effects on pain were found. However, caution must be applied
when comparing studies, as Juel et al. measured the acute effect of auricular VNS in combina-
tion with deep slow breathing implying that nVNS alone may not be adequate to modulate the
vagal tone in CP patients.
Despite unsuccessful enhancement of mean CVT in our study, nVNS could potentially be
able to module the parasympathetic tone in a sub-group of patients. A study conducted by
Farmer et al., demonstrated that the 95% confidence interval of CVT was 1.9–17.8 LVS for
healthy persons [18]. The average CVT in our study was in the lower part of the normal range,
indicating that it is likely not possible to enhance the CVT in all patients. Despite one of the
exclusion criteria was known peripheral neuropathy, some patients could have autonomic
neuropathy. Hence, some patients could have vagal neuropathy, which can make it more diffi-
cult to modulate the parasympathetic tone and potentially mediating an anti-hyperalgesic
effect [7]. A study by Liu et al. found that epilepsy patients having reduced heart rate viability
compared to healthy controls, had significantly lower effect of VNS treatment (non-respond-
ers) [31]. Thus, the effect of nVNS could be related to the degree of autonomic dysfunction,
and CVT may be useful as a screening tool in future studies. Accumulating evidence suggests
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that the autonomic nervous system plays an important role in the modulation of pain [7]. Con-
sidering that the parasympathetic nervous system acts broadly anti-nociceptive, while the sym-
pathetic nervous system acts mainly pro-nociceptive, it is implicated that a balance between
them is required for normal pain perception [32]. Thus, lack of an increase in the parasympa-
thetic tone may lead to lack of prevention of visceral pain hypersensitivity in CP patients [7].
Additionally, an imbalance between the parasympathetic and sympathetic nervous systems
may represent an important pathophysiological factor in CP patients with visceral pain. How-
ever, the latter should be investigated in detail in future studies.
Limitations
A number of study limitations need to be considered when evaluating our results. First, even
though a sample size calculation was performed prior to this study, such calculations in clinical
studies with experimental interventions are often based on some uncertain assumptions.
Hence, we could have a too small sample with a risk of false negative results regarding our pri-
mary outcomes. Second, the paradigm and parameters of nVNS may influence the effect of the
treatment including treatment duration, number of daily stimulations, stimulation intensity,
unilateral vs. bilateral stimulation, etc. In this present study, the duration of the treatment was
two weeks. There is no consensus regarding the duration of the treatment, and previous stud-
ies have used an intervention duration ranging from two weeks to six months in order to
induce pain relieving effects [3,26–28,33]. The duration of treatment seems to differ depending
on the type of disease, type of intervention (invasive VNS, auricular or cervical nVNS), and
time frame (short-term vs. long-term effect) [3]. For example, in chronic pain patients, an
auricular nVNS study applied the treatment for six weeks [34], while a cervical nVNS study
applied the treatment for two weeks [12]. Given that CP is characterized by long-lasting ail-
ment, future studies should possibly include a longer treatment duration to recover the func-
tional plasticity in neural circuits of pain processing. In addition, the duration of the wash-out
period of two weeks was chosen since it has been shown to be sufficient to reset the effects of
neuromodulation [10], but long-term effects have also been demonstrated in patients with epi-
lepsy [35]. However, if we extended the study duration (treatment and wash-out periods), a
high risk of dropout would potentially occur, and study completion would become more diffi-
cult. Third, even though the sham device did not deliver electrical stimulation, it may not be
physiologically inert as it provides some vibration and tactile sensation that potentially can
stimulate the vagal nerve and induce an effect similar to the active treatment. This could also
explain why there was no differences between the active and sham treatment, but a positive
effect when comparing both the active and sham treatments to their respective baselines. Addi-
tionally, the order of treatment sequence was, despite block randomisation, unbalanced with
more dropouts in the nVNS/sham sequence. It is unclear how this could have affected our
findings, even though the statistical analysis approach takes the treatment sequence into
account. Forth, in the current study, we did not analyse blood samples measuring inflamma-
tion. Although, no pain reductions were observed with two weeks nVNS, it would be interest-
ing to assess whether the pancreatic inflammation was decreased. Fifth, even though the study
was based on a cross-over design, where patients served as their own control, bias could be
present due to the inclusion/exclusion criteria. For instance, ongoing alcohol dependence was
an exclusion criteria whereas ongoing smoking was not, but nicotine could potentially impact
the inflammatory-system [36]. Finally, various confounding factors are present in this patient
cohort. For instance, the patients used several types of analgesics which may influence the
effect of nVNS and as already discussed it may be difficult to modulate the parasympathetic
tone for some patients. Furthermore, the impact of concomitant medication, the duration of
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CP or other disease characteristics (including stress, anxiety, and depression) could also be rel-
evant to investigate. In future studies, a larger sample size is also required in order to investi-
gate sub-groups of patients, who possible could have an effect of nVNS.
Conclusion
Our sham-controlled crossover study provided no evidence that adjuvant treatment with two
weeks nVNS induces pain relief as compared to sham treatment in patients with painful
chronic pancreatitis. Similarly, pain interference and quality of life scores were not improved
in response to nVNS as compared with sham treatment. However, attention should be directed
towards a potential pronounced sham effect of neuromodulation, since improvements were
seen for both active and sham treatments as compared to baseline.
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